Halozyme and Vertex sign deal for Hypercon technology

April 8, 2026 - 08:38

In a significant move within the biopharmaceutical industry, Halozyme Therapeutics has entered into an exclusive worldwide partnership and licensing agreement with Vertex Pharmaceuticals. The multi-faceted deal centers on Halozyme's ENHANZE® drug delivery technology, specifically its proprietary recombinant human hyaluronidase (rHuPH20), which is designed to enhance the subcutaneous delivery of biologic medicines.

Under the terms of the agreement, Vertex gains exclusive access to utilize this technology across its entire pipeline of investigational therapies. This collaboration aims to leverage the technology's potential to transform how patients receive treatment by enabling efficient delivery of medicines just under the skin, which could offer a more convenient alternative to traditional intravenous infusions.

The strategic alliance provides Halozyme with an upfront payment and makes the company eligible for potential development and commercial milestone payments, which could total up to $1.7 billion. Furthermore, Halozyme will receive tiered royalties on future global net sales of any commercialized products incorporating the technology. This partnership underscores the growing industry focus on patient-centric drug delivery solutions that can improve treatment experiences and accessibility. Both companies anticipate that this collaboration will accelerate the development of next-generation therapeutic options for serious diseases.